ClinicalTrials.gg
Not yet recruitingNCT06361979Updated Apr 12, 2024

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

A Phase 2 interventional study of SHR-A1811 and Bevacizumab in Breasr Cancer, sponsored by Huihua Xiong. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-12.

Sponsored by Huihua Xiong · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases

02

Conditions studied

  • Breasr Cancer
03

In context

Lead sponsor

Huihua Xiong is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥18 years old;
  2. confirmed -positive breast cancer;
  3. At least one measurable intracranial lesion according to RANO-BM criteria, which had not received local treatment;
  4. More than 2 weeks from last systemic treatment; patients with new brain lesions after craniocerebral surgery were admitted if no radiotherapy was performed.
  5. Prior HER2-target treatment, endocrine therapy and chemotherapy was allowed;
  6. Adequate function of major organs-

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with trastuzumab deruxtecan (DS-8201a) or any other antibody drug conjugate (ADC) which consists of an exatecan derivative that is a topoisomerase 1 inhibitor;
  2. Previous treatment with bevacizumab;
  3. Participated in other drug clinical trials within 4 weeks before admission;
  4. History of lung disease;
  5. Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
  6. According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
  7. Any other conditions that researchers believe that patients are unsuitable for this study.

    -

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ARM1

    Drug: SHR-A1811 · Drug: Bevacizumab

Interventions

06

What researchers measure

Primary outcomes

  1. CNS-ORR

    CNS-ORR was defined as percentage of participants with CNS response assessed by the investigator according to RANO-BM criteria

    Time frame: Up to 2 years

Secondary outcomes

  1. PFS

    PFS was defined as the time from first dose to first documented disease progression (PD) or death from any cause, whichever occurred first

    Time frame: up to 2 years

  2. ORR

    ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR assessed by the investigator according to RECIST version 1.1

    Time frame: Up to 2 years

  3. AE

    Proportion of participants experienced adverse events during the study period

    Time frame: Up to 2 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2024; primary completion for May 2025, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2024
First posted
Apr 12, 2024
StartEst.
May 2024
Primary completionEst.
May 2025
CompletionEst.
May 2026
Last update
Apr 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06361979
Lead sponsor
Huihua Xiong
Responsible party
Huihua Xiong (Professor, Tongji Hospital) — Sponsor-investigator
First posted
Apr 12, 2024
Start date
May 2024 (estimated)
Primary completion
May 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Apr 12, 2024

Study contacts

Xiong huihua
Contact
xionghuihua@hotmail.com
13886073988
Xiong huihua
principal investigator · Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab rezetecan

Start the discussion